FGFR4-IN-1
目录号 : GC19155
An inhibitor of FGFR4
Cas No.:1708971-72-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 0.7 nM.
FGFR4-IN-1 significantly inhibits the proliferation of HuH-7 hepatocellular carcinoma cells with IC50 of 7.8 nM[1].
References:
[1]. Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors. WO 2015059668 A1
Cell experiment: | Methylene blue staining proliferation assay (MBS): The effect of compounds on cell proliferation is assessed using HuH-7 hepatocellular carcinoma cells are cultured in the vendor-recommended medium. Specifically, 5000 cells/well are seeded in 96-well tissue culture plates in a total media volume of 100 μL/well and increasing compound dilutions or DMSO are added 24 hours thereafter in triplicates. 72 hours after compound addition, cells are fixed by adding 25 and incubated for 10 minutes at room temperature. Cells are washed three times with H2O. Cells are washed 3 times with H2O, 200 mL/well and then lysed by adding 200 mL/well of 3% HCl for 30 minutes at room temperature with shaking. Optical density is measured at A650 nm. The concentration of compound providing 50% of proliferation inhibition with respect to DMSO-treated cells is determined (IC50) using XLFit software. |
References: [1]. Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors. WO 2015059668 A1 | |
| Cas No. | 1708971-72-5 | SDF | |
| Canonical SMILES | O=C(N1CCCC2=C1N=C(C=O)C(CN3C(COCC3)=O)=C2)NC4=NC=C(C#N)C(NCCOC)=C4 | ||
| 分子式 | C24H27N7O5 | 分子量 | 493.52 |
| 溶解度 | DMSO : 6.4 mg/mL (12.97 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0263 mL | 10.1313 mL | 20.2626 mL |
| 5 mM | 0.4053 mL | 2.0263 mL | 4.0525 mL |
| 10 mM | 0.2026 mL | 1.0131 mL | 2.0263 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet